Effect of artificial liver support system on patients with severe viral hepatitis: A study of four hundred cases

Table 3 Serum amino acid levels in 25 cases before and after the first ALSS therapy (mean ± SE)

	Pre-therapy (μmol/L)	After therapy (μmol/L)
Cys	65.63 ± 41.40	53.74 ± 26.86a
Phe	94.78 ± 62.00	80.92 ± 40.75a
Ala	256.51 ± 123.73	267.84 ± 138.32
Gly	194.89 ± 83.43	212.50 ± 106.07
Glu	118.50 ± 89.65	116.85 ± 91.26
Gln	494.16 ± 218.91	515.84 ± 208.81
Met	185.85 ± 142.33	149.91 ± 134.16b
Arg	170.44 ± 231.69	143.18 ± 175.92a
Lys	220.72 ± 168.05	190.29 ± 136.28
Tyr	121.98 ± 82.82	104.44 ± 59.94a
Leu	73.73 ± 58.81	78.17 ± 43.74
Orn	113.99 ± 94.58	92.84 ± 52.93
Tau	46.41 ± 27.34	43.51 ± 32.90
Ser	123.78 ± 64.83	122.22 ± 61.29
Thr	165.60 ± 83.34	152.94 ± 83.42
Asp	16.22 ± 10.72	13.38 ± 7.87
Asn	59.40 ± 46.09	64.52 ± 49.46
Val	121.69 ± 75.01	126.35 ± 68.72
Ile	44.86 ± 36.61	46.29 ± 25.88
His	96.18 ± 73.85	87.86 ± 51.56
BCAA/AAA	1.18 ± 0.39	1.52 ± 0.77a

^aP < 0.05;

^bP < 0.001 vs pre-therapy group.